000 03653nam a22004335i 4500
001 978-94-007-0440-4
003 DE-He213
005 20140220083829.0
007 cr nn 008mamaa
008 110322s2011 ne | s |||| 0|eng d
020 _a9789400704404
_9978-94-007-0440-4
024 7 _a10.1007/978-94-007-0440-4
_2doi
050 4 _aR-RZ
072 7 _aMBGR
_2bicssc
072 7 _aMED000000
_2bisacsh
082 0 4 _a610
_223
100 1 _aVárkonyi, Judit.
_eeditor.
245 1 4 _aThe Myelodysplastic Syndromes
_h[electronic resource] /
_cedited by Judit Várkonyi.
264 1 _aDordrecht :
_bSpringer Netherlands :
_bImprint: Springer,
_c2011.
300 _aXIII, 286p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _a1. PREFACE -- 2. The history of the Myelodysplastic Syndromes -- 3. Susceptibility to MDS: DNA repair and detoxification genes -- 4. Myelodysplastic syndromes/neoplasms: Morphological and Immunohistochemical features and standard evaluation -- 5. Diagnostic Criteria and Classification of Myelodysplastic Syndromes -- 6. Cytogenetics of MDS -- 7. Molecular changes in myelodysplastic syndrome -- 8. Prognostic Scoring in MDS -- 9. Flow Cytometry in Myelodysplastic Syndromes -- 10. MDS as an Autoimmune Process -- 11. The Myelodysplastic Overlap Syndromes -- 12. Iron and copper Metabolismin the Myelodysplastic Syndromes -- 13. Pathogenesis and Management of Iron Overload in MDS -- 14. Cytokines in MDS. Abnormalities and treatment -- 15. Therapeutic Modalities and new molecular targets in MDS -- 16. Haematopoietic Stem Cell Transplantation in MDS for Adults -- 17. JMML and Myelodysplastic Syndrome in children.
520 _aMyelodysplastic syndromes (MDS) are the most common hematological malignancies involving mostly the elderly population. The major morbidity relates to patients’ symptomatic cytopenias.MDS was previously named as  “preleukemia “ or “ smoldering leukemia” as the lack of terminal cells in MDS and because about 25% of all cases progresses into acute myeloid leukemia. According to various reports the annual incidence of MDS ranges widely from 2-12 per 100.000, increasing to 30-50 cases per 100.000 among persons aged  70  or older. It is believed that the true incidence of MDS have been underestimated however it seems to be comparable to that for multiple myeloma and chronic lymphocytic leukemia.   In the past decade much progress had been made; we know more on the disease pathology, there is more emphasis on the care and more targeted therapy had been invested. Athors provide updated knowledge in this book on all clinically important aspects of the disease. Hot topics of our days are discussed in chapters by outstanding and well known scientists from all over the world. We would offer this product both for medical students and postgraduates as well as for all who are interested in this very exciting and fast progressing field of hematology. With this work authors should call attention on the disease for decision makers in healt care systems as well.  
650 0 _aMedicine.
650 0 _aHematology.
650 1 4 _aBiomedicine.
650 2 4 _aBiomedicine general.
650 2 4 _aHematology.
650 2 4 _aMedicine/Public Health, general.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789400704398
856 4 0 _uhttp://dx.doi.org/10.1007/978-94-007-0440-4
912 _aZDB-2-SBL
999 _c109289
_d109289